PMLiVE4d
Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment
Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) ...
PMLiVE6d
Innovation and flexibility in long-term follow-up studies
Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...
PMLiVE11d
GSK’s mRNA seasonal flu vaccine shows promise in younger and older adults
GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...
PMLiVE5d
Merck presents positive phase 3 results for Keytruda regimen in early-stage breast cancer
Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...
PMLiVE7d
Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types
Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...
PMLiVE8d
Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...
PMLiVE11d
The challenge of environmental management in the pharma industry
The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...
PMLiVE12d
Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...
PMLiVE13d
Gilead and AI-focused Genesis partner to develop small molecule therapies
Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...
PMLiVE14d
Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study
Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...
PMLiVE15d
FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy
The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...
PMLiVE14d
Avalere Health appoints Corrina Safeio as president, global marketing
Avalere Health has announced the appointment of Corrina Safeio as its new president, global marketing and executive vice president, corporate communications. In this role, Safeio will oversee the ...